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Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the aggressive malignancies and
mechanisms underlying its pathogenesis remain unclear. Cyclooxygenase-2 (COX-2)
enzyme system plays a crucial role in many gastrointestinal malignancies and is an impor-
tant regulator of cell growth, proliferation, apoptosis, differentiation and transformation.
More precise outcome of COX-2 in ESCC is less investigated. In this study we investigated
the risk factors of ESCC and expression of COX-2 in Carcinoma in situ (CIS) and ESCC
compared to normal esophageal mucosa. ESCC relationship to clinico-pathological param-
eters using immunohistochemistry was also part of this investigation. Current study was
conducted in the Institute of Basic Medical Sciences, Khyber Medical University, Peshawar,
Pakistan. A total of 69 diagnosed patients of ESCC, both Pakistanis and Afghans were
enrolled. Various risk factors associated with ESCC were recorded. Mean age at the time of
diagnosis was 55 years. Out of 69 patients of ESCC 46 (67%) were users of dipping tobacco
(Naswar). Expression of COX-2 was determined in normal esophageal mucosa, CIS and
invasive ESCC using Immunohistochemistry (IHC). Differences of mean were computed
using ANOVA followed by applying Post Hoc test. Patients were categorized as positive
with high expression or negative with low to nil expression. ANOVA showed large differ-
ences in expression of COX-2 in normal healthy mucosa compared with CIS and ESCC with
the mean difference of -9.529 and -7.370 respectively, p-value being <.05 at 95% confi-
dence interval (CI). No significant difference was noticed in the expression of COX-2 in CIS
compared with ESCC with p-value >.05 at 95% CI. Our complete cohort (23–85 years)
showed statistically significant difference in the expression of COX-2 gene in ESCC and CIS
tissue samples compared with normal healthy mucosa. Results of this study indicate that
over-expression of COX-2 is positively associated with ESCC.
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Introduction
Esophageal cancer (EC) is a global health concern, ranks eighth among the most common
types of cancers and is the 6th most fatal disease worldwide [1–3]. Though significant advances
have been made in the treatment of ESCC, yet in many cases, it is still unresponsive to the
treatment strategy and has an adverse prognosis, with a five year survival rate of only 10–15%
[2, 4]. EC shows marked geographical, ethnic, and gender variation. The most common histo-
logical subtype of EC in the high incidence regions such as the greater Iran is ESCC [5, 6],
while in the low incidence areas like US, esophageal adenocarcinoma is the most common sub-
type [7, 8]. In China the incidence of EC accounts for half of the cases all over the world [9].
Male to female ratio of EC mortality is 2:1 [10].
In Pakistan, esophageal cancer is quite common. Highest incidence zone for EC in Pakistan
is the Baluchistan plateau in the Northwest of Pakistan where it is the most common malig-
nancy in both males and females [5, 9, 11]. In Karachi, the largest city of Pakistan, EC is ranked
7th and 6th most common cancer in men and women respectively. The predominant type in
Karachi, Pakistan is ESCC, in contrast, adenocarcinoma is the most common variety in West-
ern countries [1]. The predominance of ESCC in Karachi needs to be viewed in the context
that the large number of people moved to Karachi from Baluchistan and north-west province
of Khyber Pakhtunkhwa (KP) [9]. According to the statistics provided by the Shaukat Khanum
Memorial Cancer Hospital and Research Center (SKMCH and RC), cancer of the esophagus is
almost 1.9 percent of the total malignancies in Pakistan. Majority of patients who were treated
in this tertiary care facility belonged to Punjab and KP [1].
Major risk factors of EC include poor socioeconomic status, use of tobacco, naswar (Snuff
or nass), use of alcohol, hot beverages and infrequent consumption of raw fruits and vegetables
[3]. Globally, different types of smokeless tobacco like chewing tobacco, wet snuff and dried
snuff are used. Fire and air cured tobacco is also used in the form of moist snuff (also called
snus). All these are used by inserting the substance inside the lips between the buccal mucosa
and gingiva [12, 13]. Chewing nass, a smokeless tobacco product, is a mixture of tobacco lime,
oil, flavoring and coloring reagent and is used in central parts of Asia and India [12, 14]. An
addictive habit like oral and nasal use of naswar is a common practice in Pushtoons of Baluchi-
stan and KP, which many studies have reported to be a risk factor of EC [9, 13].
Precise pathogenic factors and processes leading to EC are still not clear. Molecular studies
of ESCC have revealed that genetic alterations such as mutation of Tp53, loss of p16 and an
increased expression of CDKN2A play a role in the development of ESCC [15].
The American College of Pathologists classifies ESCC into different grades; well differenti-
ated, moderately and poorly differentiated carcinoma. The Pathological staging (pTNM) is
done according to American Joint Committee on Cancer (AJCC)/Union for International
Cancer Control (UICC) [16], from stage 0—stage IV, depending upon the status of the pri-
mary tumor (T), lymph node invasion (N), metastasis (M), grade and location of the tumor.
Cyclooxygenase system plays a crucial role in the progression of esophageal carcinoma
from esophagitis to dysplasia (mild, moderate and high) and invasive carcinoma (ESCC) [17].
High grade dysplasia is called CIS. Two isoforms of cyclooxygenase system are characterized
as cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is constitutively
expressed in most tissues and mediates the synthesis of prostaglandins to control normal phys-
iological functions. COX-2 is an enzyme that mediates the synthesis of prostaglandins and
thromboxanes which are the regulators of biological processes like inflammation, prolifera-
tion, angiogenesis, tumor growth and transformation [15, 17]. Overexpression of COX-2 has
been reported in many pre-malignant and malignant tissues but its mRNA and proteins were
either absent or found at a very low level in ordinary tissues. Overexpression of COX-2 was
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associated with aggressive nature of the tumor and showed reduced survival in many studies
[17–19]. A study involving Chinese patients reported that the levels of COX-2 are sufficiently
high in ESCC. This raises the possibility that selective inhibitors of COX-2 may be useful in the
prevention of this disease [20, 21]. Overexpression of COX-2 was also seen in other epithelial
malignancies, especially in the gastrointestinal tract like stomach & colon and other viscera e.g.
lung, bladder and head & neck etc. Prognostic significance is also mentioned in most of the tis-
sues [17, 18].
This study was designed to investigate the risk factors of EC in high risk population of Paki-
stan and neighboring Afghanistan. Expression of COX-2 in ESCC was also analyzed and its
correlation with clinico-pathological parameters investigated, which has not been explored in
depth so far from this region.
Material and methods
This study has been approved by the ethical review committee of Khyber Medical University.
A total of 69 cases were collected from the cardiothoracic surgical units of Lady Reading Hos-
pital (LRH) Peshawar and Rehman Medical Institute (RMI) Peshawar from March 2013 to
March 2015. Patients included 37 males and 32 females with age range of 55.3±13.73 years. All
the patients who had been diagnosed with ESCC on endoscopic biopsy had undergone esoph-
ageal resection for malignancy, were included in the study. Patients who had history of EC
other than ESCC, had irresectable tumors and those who already had received chemotherapy
or radiotherapy were excluded from the study. Patients included in the study were interviewed,
after obtaining written consent, to record information regarding age, sex, occupation, address,
level of education and personal habits like use of naswar, smoking, use of alcohol, intake of hot
beverages / raw fruits / vegetables and the level of proteins in typical diet. For the purpose of
staging, CT scan was done and reports of the patients enrolled in the study were collected. In
the resected esophagus, site and size of the tumor was recorded. Surgical specimens were col-
lected in 10% buffered formalin. Specimens were grossed and cut into sections which included
macroscopically normal esophageal mucosa (n = 40, at a distance of around 5 cm from the
tumor), adjacent dysplastic mucosa (n = 19), tumor tissue (n = 69) and any lymph nodes pres-
ent in the resected specimen. Tissue processing was done for further histopathological evalua-
tion with Haematoxylin and Eosin (H & E) staining to determine the type of tumor, grade,
depth of invasion and relevant metastatic lesion in the retrieved lymph nodes, to stage the dis-
ease according to CAP protocol 2016 (AJCC staging). [16]. The tumor tissue, dysplastic tissue
and normal healthy mucosa were further processed for immuno-histochemical staining with a
COX-2 biomarker. Clinico-histopathological results were correlated with COX-2 immuno-
expression profile.
Immuno-staining with COX-2 antibody
Immuno-histochemical analysis was performed on representative blocks of every ESCC
patient including the normal mucosa, dysplastic mucosa (wherever available) and correspond-
ing tumor tissue showing maximum cellularity. Formalin fixed paraffin embedded 3–4μm
thick sections of tissues were placed on salinized slides. The sections were de-paraffinized with
xylene and rehydrated with descending series of alcohol and subsequently washed with dis-
tilled water. For antigen retrieval, de-paraffinized slides were incubated in citrate buffer with
pH 6 in a microwave for 20 minutes. Endogenous peroxidase activity was blocked by placing
3% Hydrogen peroxidase on the slides after rinsing the slides with Phosphate Buffer Saline
(PBS). Sections were then incubated with commercially available mouse monoclonal antibody
to COX-2, clone CX 294 (Dako, Denmark) for 30 minutes, and then treated with secondary
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antibody i.e. Flex HRP. After further washing, Diaminobenzidine Tetrachloride (DAB) chro-
mogen was added. Slides were counterstained with Haematoxylin and subsequently washed.
The immuno-stained slides were assessed by two Histopathalogists independently. In case of
conflicting opinion among the two histopathologists, the cases were reviewed again by a third
histopathologist. Appropriate positive control (Smooth muscles of the same tissue) and nega-
tive control of the normal healthy mucosa of the same patient (where available) were run with
each batch.
Scoring of tumor tissue (ESCC), corresponding CIS and normal healthy
mucosa
In this study samples were scored semi-quantitatively by light microscopy with 40x magnifica-
tion, considering the proportion of stained cells and intensity of staining. In all the cases, 5
High Power Fields (HPF) of representative areas of neoplastic squamous epithelial cells were
selected and a minimum of 800–900 cells were counted manually [22]. Proportion of stained
cells were scored as 0 (0%), 1(1%), 2(1–10%), 3(11–33%) 4(34–66%), 5(>66%) respectively
[23]. Staining intensity was assessed on a scale 0 (negative), 1+ (weak), 2+ (moderate) and 3+
(strong) as reported in other studies [15, 18, 24]. Immuno-histochemical total score (histo-
score) was determined with the product of intensity and proportion score. This histoscore has
a possible range of 0–15. As reported by Binghua; median was used as a cutoff value for classifi-
cation of patients into low and high expression [25]. Median of the score was generated inde-
pendently in tumor tissue, CIS and normal corresponding tissue using SPSS version 20. The
histoscore above cutoff value of 6 was categorized as strong expression and equal to or below it
as low expression or as negative. The ESCC was compared independently with the correspond-
ing CIS and normal tissue.
Statistical analysis
SPSS version 20 was used for data entry and statistical analysis. To generate the confidence
interval of ESCC, corresponding dysplastic (CIS) and normal healthy mucosa with the bio-
marker COX-2 expression, ANOVA Test was applied. Pearson’s Chi-square test was applied to
assess the correlation of the clinico-pathological variables like age, Pakistani and Afghan popu-
lation, unhealthy habits i.e. smoking and using naswar, intake of hot beverages and dietary
habits, tumor size, pathologic grade, depth of invasion, lymph node metastasis and (AJCC)
staging of the disease with COX-2 immuno-expression. Differences were found to be statisti-
cally significant with a p-value of<0.05 as reported in other studies [18].
Results
Clinico-pathological and immuno-histochemical analysis was carried out in ESCC patients to
evaluate impact of risk factors in ESCC and COX-2 expression in different stages of cancer
development; normal squamous epithelium of 40 patients, dysplastic tissue (CIS) of 19 patients
and invasive ESCC of 69 corresponding patients. Out of 69 patients of ESCC, 46 (67%) were
users of Naswar (Table 1). Moreover among users, 87% were Afghans and 57% were Pakistani
(Fig 1). Out of 69 patients, 67% were Pakistani and 33% were Afghans. Mean age of patients at
the time of diagnosis was 55.3 ± 13.73 years (range 26-85years), 41% were� 50 years of age
and 59% were more than 50 years of age, consisting of 54% males and 46% females (with a
male to female ratio of 1.7:1). In this study we found that dysphagia is the most common com-
plaint in all the patients both for solid and liquid food. Low socioeconomic status was observed
in 99% of patients. All the patients belonged to labor class and were mostly consuming vegeta-
bles and low protein diet regularly. Rest of the risk factors like smoking, taking alcohol and
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consumption of hot beverages was studied which showed no significant correlation with
clinco-pathological parameters.
In the current study COX-2 expression in ESCC patients was investigated. In this study out
of 69 ESCC patients, strong COX-2 expression was observed in 67% of the tumor tissue of
ESCC patients whereas negative COX-2 expression was observed in 33% of patients including
both the 80% true negative and 20% weakly positive (Fig 2). In neoplastic epithelial cells
immuno-staining was predominant in the peripheral region of the tumor nest compared to
the inner cells. High grade dysplasia was found only in 28% of patients; macroscopically the
tissue CIS turned out to be mostly tumor which was expected. Among these, 79% showed
intense staining with COX-2 in upper 2/3rd of dysplastic epithelium while the basal layer was
faintly stained (Fig 3A and 3B) and negative expression was observed in 21% of the patients.
High expression of COX-2 in CIS tissues (n = 19/69) may be due to relatively small number of
paired samples of dysplastic change (CIS) compared to total number of samples of ESCC tis-
sues. Normal healthy mucosa in 40 (100%) of these patients was negative for COX-2
expression.
The correlation of COX-2 expression in normal healthy mucosa, corresponding CIS and
ESCC was determined using ANOVA test, the comparison of mean difference, significant
p-value and CI among all the three tissues is shown in Tables 2 and 3. The COX-2 immnuno-
expression in normal healthy mucosa compared with CIS tissue was significantly different
with the mean difference of -9.529, p-value 0.001 and 95% (-9.38 to -5.36) CI. Same significant
differences were observed when normal tissues were compared with ESCC with the mean
Table 1. Frequency of naswar use in esophageal squamous cell carcinoma in Khyber Pakhtunkhwa region of
Pakistan.
Tissue type Naswar use Total
User: N (%) Non-user: N (%) N (%)
ESCC 46 (67) 23 (33) 69 (100)
ESCC: Esophageal squamous cell carcinoma.
https://doi.org/10.1371/journal.pone.0205508.t001
Fig 1. Use of naswar in Pakistani and Afghan patients suffering from esophageal squamous cell carcinoma
(ESCC).
https://doi.org/10.1371/journal.pone.0205508.g001
Expression analysis of cyclooxygenase-2 in esophageal squamous cell carcinoma patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0205508 October 19, 2018 5 / 13
difference of -7.370, p-value 0.001, 95% CI of (-9.05–5.69). When the CIS was compared with
ESCC, the mean difference was -2.159 with the p-value 0.128 and CI (-4.6 to -4.78) and the dif-
ference was insignificant (Table 3).
Strong immuno-expression of COX-2 was observed in 71% of patients in the age
group� 50 years as compared to 63% of the patients in the age group >50 years. However,
with p-value� 0.05, the results are statistically insignificant. High expression of COX-2 was
seen in 65% user of naswar and 70% among non-users, though the results are statistically
Fig 2. Expression of COX-2 in normal healthy mucosa, CIS and ESCC.
https://doi.org/10.1371/journal.pone.0205508.g002
Table 2. COX-2 IHC Score using ANOVA between groups.
COX-2 IHC Score
Sum of Squares df Mean Square F p-value
Between Groups 1758.16 2 879.078 48.294 0.001
df: degree of freedom, F: ratio of means square.
https://doi.org/10.1371/journal.pone.0205508.t002
Fig 3. Immuno-histochemical expression of COX-2 in carcinoma in situ. Staining (membranous and cytoplasmic) in
upper 2/3rd of mucosa (green arrow head) (A) at low power magnification (10x) (B) at high power magnification (40x).
https://doi.org/10.1371/journal.pone.0205508.g003
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insignificant (Table 4). The tumor size of 1–3 cm, 3–7 cm and>7 cm showed strong immuno-
expression in 73%, 63% and 69% of the patients respectively, with insignificant p-value. No sig-
nificant correlation was noted with varying grades of disease, depth of invasion and lymph
node metastasis. Mild increase in the expression of COX-2 is observed with advancing stage of
the disease albeit insignificant (Table 4).
Discussion
ESCC is one of most lethal malignancies with dismal prognosis. Studies are required to
develop specific marker for targeted personalized therapy of ESCC. Increased prostanoid activ-
ity is a well-recognized characteristic of gastrointestinal, breast and lung malignancies [23, 26].
Expression of COX-2 has not been explored in ESCC and its association with clinico-patholog-
ical parameter is still not properly elucidated. Very few studies have investigated biomarker
expression of COX-2 in ESSC. These have reported increased expression of COX-2 in ESCC,
deduced through immuno-histochemical staining [27]. Study of the expression pattern of
COX-2 in ESCC is important to evaluate the role of this gene in the development of cancer and
to determine whether COX-2 selective inhibitors would be beneficial for the targeted therapy
or not.
We conducted this study to observe the impact of risk factors in ESCC and to analyze the
expression of COX-2 biomarker in ESCC. Mean age at the time of diagnosis in this study was
55 years while a study from Scotland showed median age at the time of diagnosis as 72 years
[28]. This indicates the incidence of ESCC in younger patients in this study, which may have
an association with worse prognosis [28]. Though no tumor registry exists in Pakistan, we
observed high prevalence of ESCC both in local Pushtoons of KP and Afghans in relation to
various demographic characteristics. At other places within Pakistan even higher prevalence
has been reported; only Karachi-south coastal city accounts for 5% of all the cancers in Paki-
stan. Quetta is a city in Northern Pakistan where ESCC is the third most common cancer in
men. It is noteworthy that the province of KP and the Quetta city are in close proximity to
Afghanistan and Iran where this disease is endemic [28].
In our study all male patients were either farmers or laborers while female patients were
mostly housewives. Most of the patients are from socioeconomic deprived areas, the rural
areas of KP and Afghanistan. Other studies have also reported that ESCC is higher in socioeco-
nomically deprived localities [8].
There is limited published data that have investigated the impact of naswar in ESCC in
Pakistan especially in KP [29]. This study highlights the frequency of naswar in high risk
Table 3. COX-2 IHC Score Tukey HSD: Multiple comparisons.
Dependent Variable: COX-2 IHC Score Tukey HSD
(I) Tissue type (J)Tissue type Mean Difference (I-J) p-value 95% Confidence Interval
Lower Bound Upper Bound
CIS -9.529� 0.001 -12.35 -6.71
Normal ESCC -7.370� 0.001 -9.38 -5.36
Normal 9.529� 0.001 6.71 12.35
CIS ESCC 2.159 0.128 -0.46 4.78
Normal 7.370� 0.001 5.36 9.38
ESCC CIS -2.159 0.128 -4.78 0.46
CIS, Carcinoma in situ; ESCC, Esophageal squamous cell carcinoma.
� Mean difference is significant at the 0.05 level.
https://doi.org/10.1371/journal.pone.0205508.t003
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population of KP. Majority of our patients use tobacco in different forms like dipping snuff
(naswar) as pinch which is placed under the lip between the gingival and buccal mucosa, snuff
inhalation and eating naswar. All naswar users were using naswar as pinch, 8–10 times/day
for a long period of time since the age of adolescence. Out of 69 patients of ESCC in our sam-
ple, 46 (67%) were users of naswar (Table 1), which is consistent with other published data
Table 4. Correlation of COX immuno-histochemical expression with clinico-pathological parameters.
COX-2 immuno-histochemical expression
Clinico-pathological parameters Negative expression Overexpression Total p-value
N (%) N (%) N (%)
Age �50 8 (29) 20 (71) 28(100) 0.488
>50 15 (37) 26 (63) 41(100)
69 (100)
origin Pakistan 13 22) 33 (78) 46(100) 0.206
Afghan 10 (25) 13 (75) 23(100)
69 (100)
Naswar User 16 (35) 30 (65) 46 (100) 0.718
Nonuser 7 (30) 16 (70) 23(100)
69 (100)
Smoking Yes 7 (27) 19 (73) 26(100) 0.38
No 16 (37) 27 (63) 43(100)
69 (100)
Tumor size (cm) 3-Jan 3 (25) 9 (75) 12(100) 0.74
3.1–7 15 (37) 26 (63) 41(100)
>7 5 (31) 11 (69) 16 (100)
69 (100)
Tumor grade I 9 (35) 17 (65) 26 (100) 0.588
II 10 (38) 16 (62) 26 (100)
III 4 (24) 13 (76) 17(100)
69 (100)
Stage 1 8 (36) 14 (64) 22 (100) 0.541
2 9 (39) 14 (61) 23 (100)
3 6 (29) 15 (71) 21 (100)
4 0 (00) 3 (100) 3 (100)
69 (100)
L.N invasion NX 8(40) 12 (60) 20 (100) 0.547
N0 10 (38.5) 16 (61.5) 26 (100)
N1(1–2) 4 (21) 15(79) 19 (100)
N2 (3–6) 1 (25) 3 (75) 4 (100)
69 (100)
Depth of invasion T1 0(0) 2 (100) 2(100) 0.583
T2 14 (33) 28 (66) 42(100)
T3, T4 9(36) 16 (54) 25(100)
69 (100)
Key: ESCC, Esophageal Squamous Cell Carcinoma; L.N, Lymph Node; NX, cannot be assessed; N0, no regional lymph node metastasis; N1, regional lymph node
metastasis involving 1–2 lymph node; N2, regional lymph node metastasis involving 3–6 lymph node; N, Number; T1, tumor invades lamina propria or submucosa; T2,
tumor invades muscularis propria; T3, tumor invades adventitia; T4, tumor invades adjacent structures; Tumor grade, (I: well differentiated, II: moderately
differentiated, III: Poorly differentiated, According to AJCC Staging).
https://doi.org/10.1371/journal.pone.0205508.t004
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[12, 30]. Although use of naswar was greater in patients suffering from ESCC but we could not
identify it as risk factor because normal individuals (non ESCC) were not included in this
study for comparison. Major carcinogenic constituents of naswar/snuff are N-nitrosamine and
nitrites. Others include cadmium, lead, polonium, formaldehyde and phenolic compounds
[13, 14]. ESCC may have an association with intensity, duration and cumulative amount of
snuff used. Concentration of N-nitrosamine and nitrites increases in fire and air cured pro-
cessing of loose tobacco leaves. Method of processing of snuff has not been elucidated in this
study. Our study deduced that naswar use by the patients in KP and Afghan may be a risk fac-
tor of ESCC.
Drinking alcohol is typically not practiced in this part of the world, which is one of the
major risk factor in other high risk regions. Almost all of the patients in our study were pri-
marily vegetarians and were not taking hot beverages or spicy food, rather they consumed ani-
mal protein, or fruits occasionally. This finding is different from the results reported in other
studies, showing a low intake of vegetables (fiber diet) as high risk factor for ESCC [1].
The concept of cancerization in epithelial malignancies was first proposed by Slaughter in
1953. It was proposed that genetic alteration in the progenitor/stem cells results in monoclonal
unit of altered cells in the lesion. Expansion of these genetically transformed cells acquires fur-
ther alteration in the contiguous field replacing the normal mucosa in the pre-neoplastic (dys-
plastic) lesion [31, 32]. COX-2 enzyme overexpression has been noticed in the early pre-
neoplastic field of ESCC [33].
Staining pattern of COX-2 in CIS (Fig 3A and 3B) and ESCC (Fig 4A and 4B] was both
cytoplasmic and membranous. In some of the cases, staining was seen in the cells at the periph-
ery of the tumor cell nests, suggesting that COX-2 may be associated with the proliferation of
the tumor cells. In some studies, it was revealed that a high expression of COX-2 was associated
with tumor proliferation and carcinogenesis [27, 34].
This study, using intensity of staining and percentage of stained tumor cells in all the tissue
types, found variance of expression in ESCC, CIS and normal healthy mucosa (Table 2). Cor-
relation of gene expression distinguished clearly the tumor and CIS tissue from the non-tumor
tissue. Strong COX-2 overexpression was found in 79% of dysplastic mucosa (CIS) and 67% of
corresponding invasive ESCC compared to negative expression in normal esophageal mucosa
(Fig 2). This suggests that expression of COX-2 may have a pivotal role in the progression of
epithelial cell transformation to dysplastic epithelium and invasive cancer in esophageal
mucosa. Our findings support the study of Naoki Hashimoto and Zimmermann [20, 21], who
Fig 4. Immuno-histochemical expression of COX-2 in esophageal squamous cell carcinoma. Staining (membranous &
cytoplasmic) (A) at low power magnification (10x). (B) at high power magnification [40x].
https://doi.org/10.1371/journal.pone.0205508.g004
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also noticed immuno-expression of COX-2 in ESCC in 91% of the cases and suggested that
COX-2 derived prostaglandin plays an important role in the regulation and proliferation of
tumor cells [20, 21]. Similarly, in the study of Cui COX-2 immuno-expression was noticed in
67% of the ESCC patients. However, the results of that study indicated that COX-2 expression
was significantly associated with lymph node metastasis and a poor degree of differentiation
[35]. While in another study of Hu et al [18] strong expression was found in 3/4th of the ESCC
individuals. These values are quite high than what we found in our study. The variance in the
findings could be due to a different sample size and a different ethnicity background of the
patients. Out of 46 positive cases of COX-2 expression, corresponding dysplastic epithelium
was seen in 19 patients. Out of these 19 patients, in 80%, the upper 2/3rd showed 3+ intensity
of staining (Fig 3A and 3B). These results of dysplastic epithelium are different from other
studies, in which mostly basal cells or all the dysplastic cells show COX-2 overexpression [23].
Another interesting finding in our study is that high grade dysplasia/carcinoma in-situ (CIS)
associated with invasive tumor was intensely stained in 80% of the dysplastic epithelium. This
suggests that COX-2 overexpression can also be detected in the early stage of the disease. COX-
2 overexpression was also noticed in dysplastic and ESCC tissue in the study of Yu, 2004 [33]
compared with normal mucosa, which supports the theory of pre-neoplastic field of canceriza-
tion introduced by slaughter in 1953. These results are concordant with the studies carried out
by Zhi et al., (2005) [27] and Majidi et al., (2014) [23]. We deduced from our findings that
COX-2 expression plays an important role in the progression of the disease that would help the
patients to be diagnosed and treated in the early stages of the disease.
A large number of patients below the age of 50 years were found with a high expression of
COX-2 which may be associated with the prognosis of the disease. Alidina [28] found that
ESCC at the age� 55 years influence survival. Those findings are in contrast to the findings of
Hu et al [18] who found a high expression of COX-2 in patients aged 50 years or more. Patients
of ESCC enrolled in our study showed increase frequency of naswar use. No significant differ-
ence of COX-2 expression was noticed among naswar user and nonusers. Though consump-
tion of alcohol is considered as a risk factor in some studies [1], however, our patients had no
history of consumption of alcohol. Similarly, smoking history was also correlated but p-values
were not significant. Relevant literature also suggests that in less developed countries, smoking
does not play a role in high prevalence of ESCC [17].
There was no significant statistical difference found with increasing tumor size, varying
grades, lymph node invasion, and depth of invasion, stage of the disease and their expression
of COX-2 (Table 4). The lack of overexpression of COX-2 with statistically insignificant clin-
ico-pathological variables could be due to lesser number of cases in our study. Our results are
similar to those reported by Kuo et al [34] who also found that overexpression of COX-2 was
associated with fewer metastasis and less advanced malignancy. Whereas our results are not
consistent with the findings of other studies [27, 36–39], showing COX-2 overexpression was
significantly associated with the tumor invasion and disease stage.
In several other studies it was noticed that COX-2 promotes proliferation, angiogenesis and
inhibits apoptosis [40]. In current study, overexpression of COX-2 in CIS and ESCC tissue
may be associated with the progression of the disease. Our findings suggest that COX-2 can be
used as a potential predictive biomarker. In addition to this, selective inhibitors of COX-2 like
non-steroidal anti-inflammatory drugs could possibly play a role in the prevention of such
malignancies [17].
Two limitations of this study are noteworthy. First, sample size of this study is relatively
small, to assess the correlation of COX-2 expression with the clinico-pathological parameters.
Second, normal individuals i.e. those not suffering from cancer, and use naswar were not
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included in the study. Therefore we could not establish a link whether naswar is a risk factor,
even though a large number of patients were found to be using naswar.
Conclusion
Naswar use is more common in patients of ESCC in the KP province of Pakistan and is even
more prevalent in the neighboring Afghanistan. We observed high prevalence of ESCC despite
the high use of vegetable diet and non-use of spicy food and hot beverages. High occurrence of
this disease demands aggressive measures to prevent the incidence of this disease. It also high-
lights the need for improved public health practices to reduce the addiction to tobacco and
snuffing. The cohort 23–85 years shows statistically significant difference in expression of
COX-2 gene in ESCC and CIS tissue sample compared with normal healthy mucosa. Over-
expression of COX-2 is positively associated with ESCC. Further studies on a larger scale are
needed to confirm the prognostic and predictive value of COX-2 in this high risk population.
High expression of COX-2 in ESCC may be potentially beneficial using COX-2 inhibitors.
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